Immune-mediated adverse rheumatic reactions following administration of immune checkpoint inhibitors
Immunotherapy with immune checkpoint inhibitors (ICIs) opens up new prospects in treatment of malignancies, although this novel therapy quite often results in development of immune-related adverse events (irAEs), which can limit their clinical use. IrAEs can affect almost any organ system, including...
Saved in:
Main Authors: | I. V. Menshikova, V. V. Strogonova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA PRESS LLC
2020-09-01
|
Series: | Научно-практическая ревматология |
Subjects: | |
Online Access: | https://rsp.mediar-press.net/rsp/article/view/2934 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
IMMUNE CHECKPOINT INHIBITION AND AUTOIMMUNITY: RHEUMATOLOGICAL PROBLEMS
by: E. L. Nasonov
Published: (2018-03-01) -
Cancer therapeutic implications of microRNAs in the regulation of immune checkpoint blockade
by: Yan Zhang, et al.
Published: (2019-08-01) -
PREDICTIVE RESPONSE MARKERS FOR IMMUNE RESPONSE BLOCKS
by: G. A. Janus, et al.
Published: (2020-09-01) -
Immune Response Checkpoint Inhibitors: New Risks of a New Class of Antitumor Agents
by: E. V. Shubnikova, et al.
Published: (2020-03-01) -
Changes in the level of immune checkpoints in patients with various forms of autoimmune thyroiditis
by: V. V. Babinsky
Published: (2024-09-01)